AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca ultomiris (ravulizumab) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, Q2 2026
1,314
Period ended Jun 30, 2026
Change on a year earlier
+11.6%
1,177 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up ultomiris (ravulizumab) — worldwide product sales ($m)
- Ultomiris (ravulizumab) — Worldwide YoY actual (%)12.0% · Q2 2026
- Ultomiris (ravulizumab) — Worldwide YoY CER (%)12.0% · Q2 2026
- Ultomiris (ravulizumab) — US product sales ($M)719 · Q2 2026
- Ultomiris (ravulizumab) — Emerging Markets product sales ($M)87 · Q2 2026
- Ultomiris (ravulizumab) — Europe product sales ($M)307 · Q2 2026
- Ultomiris (ravulizumab) — Established RoW product sales ($M)201 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) — Worldwide product sales ($M) ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_ultomiris_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.